FDA Approves New Immunotherapy Combination for Platinum-Resistant Ovarian Cancer
If you or someone you love has heard the phrase “platinum-resistant,” you already know it lands like a door closing. Platinum-based chemotherapy — carboplatin, cisplatin — is the backbone of ovarian cancer treatment. When a cancer stops responding to it, the list of good options gets very short, very fast.
On February 10, 2026, that list got longer. The FDA approved pembrolizumab (you may know it by its brand name, Keytruda) combined with the chemotherapy drug paclitaxel, with or without bevacizumab (Avastin), for people with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. It is the first immunotherapy regimen ever approved for this situation.
We want to walk you through what that actually means — not in trial-speak, but in plain language.
First, what “platinum-resistant” really means
Chemotherapy works by poisoning cells that divide quickly. Cancer cells divide quickly, so they take the biggest hit. But cancer is a shapeshifter. Over months and treatment cycles, some cells learn to survive the poison — they pump the drug back out, repair the damage faster, or simply stop doing the thing the drug punishes them for.
When a cancer comes back within six months of finishing platinum chemo, doctors call it platinum-resistant. It isn’t a failure of the patient or the doctor. It’s the cancer adapting. And until now, the treatments available afterward have mostly bought time in months, not years.
How immunotherapy is different
Chemotherapy attacks the cancer. Immunotherapy does something stranger and, in a way, more elegant: it removes the cancer’s disguise so your own immune system can attack it.
Here’s the ELI5 version. Your immune system has T cells — think of them as patrol officers trained to spot and destroy anything that looks wrong. To keep those officers from attacking healthy tissue, your body gives them “brakes,” built-in checkpoints that say stand down, this cell is one of ours.
Tumors figure out how to press those brakes. Many ovarian cancers coat themselves in a protein called PD-L1, which is essentially a forged badge. When a T cell reads that badge, its brake engages and it walks right past a cancer cell it should have destroyed.
Pembrolizumab is a checkpoint inhibitor. It cuts the brake line. It doesn’t kill cancer itself — it just stops the cancer from talking the immune system out of doing its job. Pair that with paclitaxel (which damages tumor cells and spills their contents, making them easier for the immune system to notice), and the two work better together than either does alone.
What the trial showed
The approval rests on KEYNOTE-B96, an international trial of 643 people whose cancer had progressed after one or two prior treatments.
Among participants whose tumors were PD-L1 positive:
- Overall survival was about 18 months with the pembrolizumab combination, compared with about 14 months without it.
- Progression-free survival — the time before the cancer grew again — improved by roughly a month, from about 7 months to about 8.
Four months. We want to be honest about that number, because we know how it can read on a hard day. Four months is not a cure, and no one at the FDA is pretending otherwise.
But four months in this setting is also genuinely significant. This is one of the strongest overall-survival results ever reported in platinum-resistant ovarian cancer, and it’s the first Phase 3 trial in this indication to show a meaningful survival benefit rather than just a delay in tumor growth. Those four months are the median, too — meaning half the group did better than that, some considerably. For a disease where progress has come in inches, this is a real step.
The test that comes with it
The FDA approved a companion diagnostic alongside the drug — a lab test that checks whether a tumor is PD-L1 positive.
A companion diagnostic is simply a test that tells you whether a specific treatment is likely to work for you. Think of it as checking the lock before buying the key. Because pembrolizumab works by stripping away the PD-L1 disguise, it makes sense that it helps most in tumors that are actually wearing one. If your tumor doesn’t make PD-L1, this particular approach has less to work with.
If you’re facing platinum-resistant disease, this is a concrete question to bring to your oncologist: has my tumor been tested for PD-L1? It may already be in your pathology report.
What it feels like to take
Immunotherapy has a real side-effect profile, and it’s a different one from chemo. The common effects reported in the trial included fatigue, rash, fever, mouth sores, cough, joint and muscle pain, thyroid changes, urinary tract infections, digestive upset, and hand-foot syndrome.
The more serious risks come from the same mechanism that makes the drug work. When you release the immune system’s brakes, it can occasionally attack healthy tissue too — most often the thyroid, but sometimes the colon, lungs, liver, kidneys, skin, pancreas, or the small hormone glands. These reactions are usually manageable when caught early, which is exactly why care teams monitor bloodwork closely and want to hear about new symptoms right away rather than at your next scheduled visit.
Two more drugs got a fast pass
February also brought good news on a class of drugs called antibody-drug conjugates, or ADCs — and these are worth understanding, because they’re where a lot of the field’s energy is going.
An ADC is a guided missile. One half is an antibody: a homing device that locks onto a specific protein found on cancer cells and mostly not on healthy ones. The other half is a chemotherapy payload, attached with a chemical tether. The antibody finds the tumor, the cell swallows the whole package, and only then does the chemo get released — inside the cancer cell, rather than everywhere in your body at once. More punch to the tumor, less collateral damage to you.
Two ADCs now hold FDA Breakthrough Therapy designation for platinum-resistant ovarian cancer:
- Raludotatug deruxtecan, which targets a protein called CDH6
- Sofetabart mipitecan, which targets folate receptor alpha
Breakthrough designation isn’t approval. It’s the FDA saying the early data here look promising enough that we’re going to work alongside you and move quickly. Both drugs are now enrolling Phase 3 trials — the large, final-stage studies that determine whether a drug gets approved. If you’re considering trial participation, these are names worth asking about.
What this month means
February 2026 gave us a first — the first immunotherapy approved for a stage of this disease that has been stubbornly resistant to almost everything — plus two smart-bomb drugs on the fast track behind it.
None of this is a cure. All of it is momentum. And momentum, in ovarian cancer research, has been a long time coming.
If any of this raises questions about your own care, write them down and bring them to your next appointment. Good questions to start with: Has my tumor been tested for PD-L1? For folate receptor alpha? Am I eligible for any trials enrolling right now? You are allowed to ask. You are allowed to keep asking.
Sources